Human HER2 and PI3K H1047R cooperate to promote mammary tumorigenesis in vivo

被引：0
|
作者：
Hanker, Ariella B. [1 ]
Kuba, Maria G. [1 ]
Sanchez, Violeta [1 ]
Sutton, Cammie R. [1 ]
Pfefferle, Adam [2 ]
Balko, Justin M. [1 ]
Perou, Charles M. [2 ]
Cook, Rebecca S. [1 ]
Arteaga, Carlos L. [1 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] Univ N Carolina, Sch Med, Chapel Hill, NC USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-4875
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4875
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K
    Yueh, Alexander E.
    Payne, Susan N.
    Leystra, Alyssa A.
    Van De Hey, Dana R.
    Foley, Tyler M.
    Pasch, Cheri A.
    Clipson, Linda
    Matkowskyj, Kristina A.
    Deming, Dustin A.
    [J]. PLOS ONE, 2016, 11 (02):
  • [2] Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein
    Ketcham, John M.
    Harwood, Stephen J.
    Aranda, Ruth
    Aloiau, Athenea N.
    Bobek, Briana M.
    Briere, David M.
    Burns, Aaron C.
    Haatveit, Kersti Caddell
    Calinisan, Andrew
    Clarine, Jeffery
    Elliott, Adam
    Engstrom, Lars D.
    Gunn, Robin J.
    Ivetac, Anthony
    Jones, Benjamin
    Kuehler, Jon
    Lawson, J. David
    Nguyen, Natalie
    Parker, Cody
    Pearson, Kelly E.
    Rahbaek, Lisa
    Saechao, Barbara
    Wang, Xiaolun
    Waters, Anna
    Waters, Laura
    Watkins, Ashlee H.
    Olson, Peter
    Smith, Christopher R.
    Christensen, James G.
    Marx, Matthew A.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (06) : 4936 - 4949
  • [3] Allosteric Modulation of WT and H1047R Mutant PI3Kα Investigated by MD Simulations
    Gkeka, Paraskevi
    Evangelidis, Thomas
    Cournia, Zoe
    [J]. BIOPHYSICAL JOURNAL, 2013, 104 (02) : 402A - 402A
  • [4] Motility of human colorectal cancer cells is promoted by H1047R kinase mutation of PI3K p110-alpha
    Wan, Guanghua
    Ongchin, Melanie
    Hand, Essence
    Rajput, Ashwani
    [J]. CANCER RESEARCH, 2012, 72
  • [5] Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3Kα H1047R mutant inhibitors
    Zhang, Ning
    Yu, Zhimei
    Yang, Xiaohong
    Zhou, Yan
    Wang, Jia
    Zhang, Shao-Lin
    Wang, Ming-Wei
    He, Yun
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 158 : 707 - 719
  • [6] Discovery of HP567, a highly potent, brain-penetrating, and H1047R-selective PI3K α inhibitor for the treatment of tumors bearing H1047R mutation
    Li, Jing
    Fan, Lei
    Liu, Chengcheng
    Luo, Yao
    Chu, Xiaohui
    Yu, Hua
    Wang, Fei
    Li, Xinghai
    [J]. CANCER RESEARCH, 2024, 84 (07)
  • [7] Structural Perturbations due to Mutation (H1047R) in Phosphoinositide-3-kinase (PI3Kα) and Its Involvement in Oncogenesis: An in Silico Insight
    Sharma, Jatin
    Bhardwaj, Vijay
    Purohit, Rituraj
    [J]. ACS OMEGA, 2019, 4 (14): : 15815 - 15823
  • [8] N-Phenyl-4-hydroxy-2-quinolone-3-carboxamides as selective inhibitors of mutant H1047R phosphoinositide-3-kinase (PI3Kα)
    Sabbah, Dima A.
    Simms, Neka A.
    Wang, Wang
    Dong, Yuxiang
    Ezell, Edward L.
    Brattain, Michael G.
    Vennerstrom, Jonathan L.
    Zhong, Haizhen A.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (24) : 7175 - 7183
  • [9] LOXO-783: A potent, highly mutant selective and brain-penetrant allosteric PI3Kα H1047R inhibitor in combination with standard of care (SOC) treatments in preclinical PI3Kα H1047R-mutant breast cancer models
    Puca, Loredana
    Dowless, Michele S.
    Perez-Ferreiro, Carmen M.
    Ortiz-Ruiz, Maria Jesus
    Donoho, Gregory P.
    Capen, Andrew
    Huber, Lysiane
    Bogner, Sarah M.
    Fei, Dongling
    Manro, Jason R.
    Yu, Chun Ping
    Xu, Wei Guo
    Wang, Rui
    Chen, Shuang
    Hicks, Mark A.
    Zolfaghari, Parisa
    Faber, Andrew
    Gilmour, Raymond
    Ramstetter, Monica D.
    Chang, Matthew T.
    Lallena, Maria Jose
    Gong, Xuequian
    Hyman, David M.
    Smyth, Lillian M.
    Brandhuber, Barbara J.
    Taylor, Barry S.
    Klippel, Anke
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [10] HER2/PIK3CAH1047R transgenic mammary tumors develop acquired resistance to triple therapy with trastuzumab, pertuzumab and PI3K inhibitors via multiple mechanisms
    Hanker, Ariella B.
    Bulen, Benjamin
    Brewer, Monica Red
    Young, Christian D.
    Farrar, Kirsten M.
    Cook, Rebecca S.
    Stricker, Thomas P.
    Arteaga, Carlos L.
    [J]. CANCER RESEARCH, 2015, 75
12345